Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares
Evotec SE has filed a registration statement with the SEC for a proposed offering of shares represented by American Depositary Shares (ADSs) in the U.S. The exact number and price of ADSs are yet to be determined. Evotec aims for a secondary listing on the Nasdaq Global Select Market under the ticker symbol EVO. The offering will be led by BofA Securities and Morgan Stanley as joint book-running managers. The registration statement has not yet become effective, and no sales of these securities can occur until it does.
- Proposed secondary listing on the Nasdaq could increase visibility and liquidity.
- Partnership with established financial institutions (BofA, Morgan Stanley) for the offering.
- The registration statement has not yet become effective, delaying the offering.
- No assurance of successful completion of the offering due to inherent risks.
HAMBURG, GERMANY / ACCESSWIRE / October 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares ("ADSs"). The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.
Evotec's shares are listed on the regulated market of the Frankfurt Stock Exchange in Germany with additional admission obligations of the Prime Standard Segment. Evotec has applied for a secondary listing of the ADSs on the Nasdaq Global Select Market in the United States under the ticker symbol "EVO". The new shares underlying the ADSs will be issued from Evotec's authorised capital.
The ADSs will be issued under Evotec's revised ADS program, which continues to be administered by JP Morgan Chase Bank, N.A. BofA Securities and Morgan Stanley are acting as lead joint book-running managers for the offering. Citigroup, Jefferies, Cowen and RBC Capital Markets are acting as joint book-running managers for the offering.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from BofA Securities, NC1-004-03-43; 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@bofa.com, Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.
ABOUT EVOTEC SE
Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Evotec's mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. Evotec has built a comprehensive suite of fully integrated, next generation technology platforms which it believes will transform the way new drugs are discovered. By leveraging the advanced capabilities of Evotec's integrated platforms, Evotec is able to provide solutions to its partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Among the factors that may result in differences include risks indicated in the risk factors included in Evotec's Registration Statement on Form F-1 and other filings with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
INVESTOR RELATIONS CONTACT:
volker.braun@evotec.com,
T. +49.(0)40.560 81-775
F. +49.(0)40.560 81-333
SOURCE: Evotec AG
View source version on accesswire.com:
https://www.accesswire.com/667523/Evotec-SE-files-Registration-Statement-for-Proposed-Offering-of-American-Depositary-Shares
FAQ
What did Evotec announce on October 11, 2021?
What is the ticker symbol for Evotec's proposed ADSs on Nasdaq?
Who are the lead managers for Evotec's offering?
Why has the registration statement not yet become effective?
What could impact the completion of Evotec's proposed offering?
